PRESS RELEASES

Date Title and Summary View
Toggle Summary Regulus Initiates Multiple Ascending Dose Study in Healthy Volunteers of RGLS4326 for the Treatment of ADPKD
Initial safety and pharmacokinetic results from single ascending dose study support advancement LA JOLLA, Calif. , May 1, 2018 /PRNewswire/ --  Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs,
View HTML
Toggle Summary Kathryn J. Collier Joins Regulus Board of Directors
LA JOLLA, Calif. , April 17, 2018 /PRNewswire/ --  Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced Kathryn J. Collier has joined the Company's board of directors.
View HTML
Toggle Summary Regulus to Present at the Needham Healthcare Conference
LA JOLLA, Calif. , March 20, 2018 /PRNewswire/ --  Regulus Therapeutics Inc . (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Jay Hagan , President and Chief Executive Officer of Regulus, will
View HTML
Toggle Summary Regulus Reports Fourth Quarter and Year-end 2017 Financial Results and Pipeline Update
Full enrollment of RG-012 studies anticipated in 2H 2018 RGLS4326 Phase I study on track Conference call today at 5:00 p.m. ET LA JOLLA, Calif. , March 7, 2018 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company leading the discovery and development of innovative
View HTML
Toggle Summary Regulus to Present at the Cowen and Company 38th Annual Health Care Conference
LA JOLLA, Calif. , March 5, 2018 /PRNewswire/ --  Regulus Therapeutics Inc . (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Jay Hagan , President and Chief Executive Officer of Regulus, will present
View HTML
Toggle Summary Regulus to Provide Fourth Quarter and Year-end 2017 Financial Results on March 7, 2018
Conference Call and Webcast to Follow LA JOLLA, Calif. , Feb. 28, 2018 /PRNewswire/ --  Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced it will provide fourth quarter and
View HTML
Toggle Summary Regulus to Participate in the LEERINK Partners 7th Annual Global Healthcare Conference
LA JOLLA, Calif. , Feb. 8, 2018 /PRNewswire/ --  Regulus Therapeutics Inc . (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Dan Chevallard , Chief Financial Officer of Regulus, will participate in a
View HTML
Toggle Summary Regulus Announces First-in-Human Dosing for Phase I Study of RGLS4326 for the Treatment of Autosomal Dominant Polycystic Kidney Disease
LA JOLLA, Calif. , Dec. 19, 2017 /PRNewswire/ --  Regulus Therapeutics Inc . (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has initiated the first-in-human Phase I study of RGLS4326 and
View HTML
Toggle Summary Regulus Reports Third Quarter 2017 Financial Results and Recent Events
Conference Call Today at 5:00 p.m. ET LA JOLLA, Calif. , Nov. 7, 2017 /PRNewswire/ --  Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today summarized recent events and reported financial
View HTML
Toggle Summary Regulus to Provide Third Quarter 2017 Financial Results on November 7, 2017
Conference Call and Webcast to Follow LA JOLLA, Calif. , Oct. 31, 2017 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced it will provide third quarter 2017
View HTML